摘要
目的:探讨通心络胶囊治疗偏头痛临床疗效分析及安全性评价,为临床诊断治疗提供参考。方法:将本组62例偏头痛患者根据随机数字表法随机分为对照组(n=31)和观察组(n=31)。两组患者均给予维生素B1、维生素B12和谷维素常规治疗;对照组给予盐酸氟桂利嗪胶囊治疗,观察组给予通心络胶囊治疗。两组患者均以4周为1个治疗疗程,2个疗程结束后观察其疗效、NO、ET-1及不良反应。结果:观察组治疗后总有效率(87.10%)显著高于对照组(64.52%),且有显著性差异(P<0.05);两组治疗后ET-1含量显著低于各组间治疗前,且差异具有统计学意义(P<0.05);观察组治疗后ET-1含量(63.24±12.23)umol/L显著低于对照组(70.09±13.09)umol/L,且差异具有统计学意义(P<0.05);两组治疗后NO含量显著低于各组间治疗前,且差异具有统计学意义(P<0.05);观察组治疗后NO含量(73.91±10.37)ng/L低于对照组(78.27±11.29)ng/L,但差异不具有统计学意义(P<0.05);两组不良反应比较不具有显著性差异(P>0.05)。结论:通心络胶囊治疗偏头痛疗效显著,不良反应较轻,临床上应用安全可靠,值得推广。
Objective： To investigate the clinical efficacy and safety evaluation analysis of Tongxinluo Capsule treating migraine and to provide a reference for clinical diagnosis and treatment. Methods： 62 patients with migraine were randomly divided according to the random number table into the control group（ n = 31） and observation group（ n = 31）. All patients were given vitamin B1,vitamin B12 and oryzanol conventional treatment. The control group was given Flunarizine Hydrochloride Capsules treatment and the observation group given Tongxinluo Capsule treatment. 4 weeks was a course of treatment. The efficacy,NO,ET- 1 and adverse reactions after two courses were evaluated. Results： The total effective rate（ 87. 10%） in the observation group was significantly higher than that（ 64. 52%） of the control group after treatment and there was significant difference（ P〈0. 05）. After treatment,ET- 1 levels were significantly lower than those before treatment and the difference was statistically significant（ P〈0. 05）. In the observation group after treatment,ET- 1 levels（ 63. 24 ± 12. 23） μmol / L was significantly lower than（ 70. 09 ± 13. 09） μmol / L of the control group and the difference was statistically significant（ P〈0. 05）. After treatment,NO content was significantly lower than those before treatment in each group and the difference was statistically significant（ P〈0. 05）. NO levels after treatment in the observation group was（ 73. 91 ± 10. 37） ng / L lower than（ 78. 27 ± 11. 29） ng / L of the control group and the difference was not statistically significant（ P〈0. 05）. Two groups＇ adverse reactions had no significant difference（ P〉0. 05）. Conclusion： Tongxinluo Capsule treating migraine has significant effect and fewer adverse reactions. It is safe,reliable and worthy of promotion.
出处
《中华中医药学刊》
CAS
2014年第12期3067-3069,共3页
Chinese Archives of Traditional Chinese Medicine
关键词
通心络胶囊
偏头痛
疗效
全性评价
Tongxinluo Capsule
migraine
efficacy
safety evaluation
